ArticleFrontiers in pharmacology2026
Paeoniflorin alleviates CKD-associated constipation by modulating TPH1/AHR-related signaling and suppressing NLRP3/GSDMD-mediated pyroptosis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Constipation is a common complication of chronic kidney disease (CKD) and contributes to a vicious cycle linking intestinal dysfunction and renal injury, yet effective targeted therapies remain limited. Paeoniflorin (PF), a major bioactive constituent of Paeonia lactiflora Pall., has reported renoprotective and gastrointestinal regulatory effects, but its role in CKD-associated constipation remains unclear. Methods: In this study, we investigated the therapeutic effects and underlying mechanisms of PF in an adenine-induced mouse model of CKD-associated constipation. Constipation-related phenotypes, renal function, renal and colonic histopathology, intestinal barrier markers, TPH1/AHR-related signaling, renal NLRP3/GSDMD-mediated pyroptosis, gut microbial composition, PCS-related metabolic alterations, and molecular docking with key enzymes involved in the tyrosine-p-cresol-PCS pathway were assessed. Results: PF dose-dependently improved constipation-related phenotypes and renal dysfunction, and the high-dose PF group was selected for subsequent mechanistic analyses. High-dose PF attenuated renal fibrosis, restored colonic mucosal architecture, and increased the expression of tight junction proteins. Mechanistically, PF upregulated TPH1 and AHR expression, suggesting modulation of TPH1/AHR-related signaling. In renal tissues, PF suppressed NLRP3/GSDMD-mediated pyroptosis and improved the expression of KCNK3 and OAT3. PF also selectively reshaped gut microbial composition and was associated with microbial functional changes related to amino acid metabolism and inflammatory signaling. In addition, PF was associated with PCS-related metabolic alterations and showed potential interactions with key enzymes involved in the tyrosine-p-cresol-PCS pathway. Discussion: These findings indicate that PF alleviated CKD-associated constipation and improved renal injury, possibly through integrated modulation of intestinal barrier integrity, gut microbial composition, TPH1/AHR-related signaling, and renal pyroptosis-related signaling. PF may therefore represent a potential pharmacological candidate for CKD-associated constipation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.